deltatrials
Active Not Recruiting PHASE1 NCT02494167

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

Administration of Donor Derived Multi-Tumor-Associated Antigen (TAA)- Specific T Cells to Patients With AML or MDS (ADSPAM)

Sponsor: American Society for Blood and Marrow Transplantation (ASBMT)

Conditions Acute Myeloid Leukemia Myelodysplastic Syndrome
Interventions MultiTAA-specific T cells
Updated 20 times since 2017 Last updated: Oct 20, 2025 Started: Feb 29, 2016 Primary completion: Apr 30, 2025 Completion: Feb 28, 2027

This PHASE1 trial investigates Acute Myeloid Leukemia and Myelodysplastic Syndrome and is currently ongoing. American Society for Blood and Marrow Transplantation (ASBMT) leads this study, which shows 20 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2018 · 13 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Jul 2019 · 6 months · monthly snapshot~Jul 2019 – ~Jan 2020 · 6 months · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Jul 2022 · 5 months · monthly snapshot~Jul 2022 – ~Jul 2023 · 12 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2025 · 14 months · monthly snapshot~Nov 2025 – present · 5 months · monthly snapshot

Change History

20 versions recorded

  1. Nov 2025 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  2. Sep 2024 — Nov 2025 [monthly]

    Recruiting PHASE1

  3. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  4. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1

  5. Jul 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

▶ Show 15 earlier versions

  1. Jul 2022 — Jul 2023 [monthly]

    Recruiting PHASE1

  2. Feb 2022 — Jul 2022 [monthly]

    Recruiting PHASE1

  3. Oct 2021 — Feb 2022 [monthly]

    Recruiting PHASE1

  4. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  6. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Mar 2020 — Aug 2020 [monthly]

    Recruiting PHASE1

  8. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE1

  9. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1

  10. Jul 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  11. Jan 2019 — Jul 2019 [monthly]

    Recruiting PHASE1

  12. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE1

  13. May 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  14. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE1

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • American Society for Blood and Marrow Transplantation (ASBMT)
  • Baylor College of Medicine
  • Cancer Prevention Research Institute of Texas
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • The Methodist Hospital Research Institute
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations